Harmonization of neuroimaging biomarkers for neurodegenerative diseasesCitation formats

  • Authors:
  • SRA-NED JPND Working Group

Standard

Harmonization of neuroimaging biomarkers for neurodegenerative diseases : A survey in the imaging community of perceived barriers and suggested actions. / SRA-NED JPND Working Group.

In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 11, 01.12.2019, p. 69-73.

Research output: Contribution to journalArticle

Harvard

SRA-NED JPND Working Group 2019, 'Harmonization of neuroimaging biomarkers for neurodegenerative diseases: A survey in the imaging community of perceived barriers and suggested actions' Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, vol. 11, pp. 69-73. https://doi.org/10.1016/j.dadm.2018.11.005

APA

Vancouver

Author

SRA-NED JPND Working Group. / Harmonization of neuroimaging biomarkers for neurodegenerative diseases : A survey in the imaging community of perceived barriers and suggested actions. In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 2019 ; Vol. 11. pp. 69-73.

Bibtex

@article{3a039ac2f1454b189eb463d0d205cb42,
title = "Harmonization of neuroimaging biomarkers for neurodegenerative diseases: A survey in the imaging community of perceived barriers and suggested actions",
abstract = "Introduction: Molecular, functional, and structural neuroimaging biomarkers are largely used to study neurodegenerative diseases, but their benefits to patients/science might be greatly enhanced by improving standardization and cross-validation. In this EU Joint Programme-Neurodegenerative Diseases Research–funded project, we surveyed the neuroimaging community to assess perceived barriers in multicentric neuroimaging harmonization and actions to overcome them. Methods: An anonymous survey addressed researchers, clinicians, pharma industry, and professional associations, inquiring about both general and modality-specific harmonization barriers. Results: Survey participants (459) represented an international (37 countries) multidisciplinary community. We identified two sets of funding actions, one proposing the creation of an updated hub of documents to help researchers plan and execute multicentric neuroimaging studies capitalizing from previous studies, and the other focused on modality-specific harmonization challenges in future neurodegenerative diseases clinical trials. Discussion: This large survey of priorities and actions may help define harmonization calls launched by worldwide science funding agencies.",
keywords = "Biomarker, EEG, Electroencephalography, Harmonization, Magnetic resonance imaging, MRI, Multicentric, Multisite, Neurodegeneration, Neuroimaging, PET, Photon emission computed tomography, Positron emission tomography, SPECT, Survey",
author = "{SRA-NED JPND Working Group} and Jorge Jovicich and Frederik Barkhof and Claudio Babiloni and Karl Herholz and Christoph Mulert and {van Berckel}, {Bart N.M.} and Frisoni, {Giovanni B.}",
year = "2019",
month = "1",
day = "10",
doi = "10.1016/j.dadm.2018.11.005",
language = "English",
volume = "11",
pages = "69--73",
journal = "Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring",
issn = "2352-8729",
publisher = "Elsevier BV",

}

RIS

TY - JOUR

T1 - Harmonization of neuroimaging biomarkers for neurodegenerative diseases

T2 - A survey in the imaging community of perceived barriers and suggested actions

AU - SRA-NED JPND Working Group

AU - Jovicich, Jorge

AU - Barkhof, Frederik

AU - Babiloni, Claudio

AU - Herholz, Karl

AU - Mulert, Christoph

AU - van Berckel, Bart N.M.

AU - Frisoni, Giovanni B.

PY - 2019/1/10

Y1 - 2019/1/10

N2 - Introduction: Molecular, functional, and structural neuroimaging biomarkers are largely used to study neurodegenerative diseases, but their benefits to patients/science might be greatly enhanced by improving standardization and cross-validation. In this EU Joint Programme-Neurodegenerative Diseases Research–funded project, we surveyed the neuroimaging community to assess perceived barriers in multicentric neuroimaging harmonization and actions to overcome them. Methods: An anonymous survey addressed researchers, clinicians, pharma industry, and professional associations, inquiring about both general and modality-specific harmonization barriers. Results: Survey participants (459) represented an international (37 countries) multidisciplinary community. We identified two sets of funding actions, one proposing the creation of an updated hub of documents to help researchers plan and execute multicentric neuroimaging studies capitalizing from previous studies, and the other focused on modality-specific harmonization challenges in future neurodegenerative diseases clinical trials. Discussion: This large survey of priorities and actions may help define harmonization calls launched by worldwide science funding agencies.

AB - Introduction: Molecular, functional, and structural neuroimaging biomarkers are largely used to study neurodegenerative diseases, but their benefits to patients/science might be greatly enhanced by improving standardization and cross-validation. In this EU Joint Programme-Neurodegenerative Diseases Research–funded project, we surveyed the neuroimaging community to assess perceived barriers in multicentric neuroimaging harmonization and actions to overcome them. Methods: An anonymous survey addressed researchers, clinicians, pharma industry, and professional associations, inquiring about both general and modality-specific harmonization barriers. Results: Survey participants (459) represented an international (37 countries) multidisciplinary community. We identified two sets of funding actions, one proposing the creation of an updated hub of documents to help researchers plan and execute multicentric neuroimaging studies capitalizing from previous studies, and the other focused on modality-specific harmonization challenges in future neurodegenerative diseases clinical trials. Discussion: This large survey of priorities and actions may help define harmonization calls launched by worldwide science funding agencies.

KW - Biomarker

KW - EEG

KW - Electroencephalography

KW - Harmonization

KW - Magnetic resonance imaging

KW - MRI

KW - Multicentric

KW - Multisite

KW - Neurodegeneration

KW - Neuroimaging

KW - PET

KW - Photon emission computed tomography

KW - Positron emission tomography

KW - SPECT

KW - Survey

U2 - 10.1016/j.dadm.2018.11.005

DO - 10.1016/j.dadm.2018.11.005

M3 - Article

VL - 11

SP - 69

EP - 73

JO - Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

JF - Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

SN - 2352-8729

ER -